○Daisuke Kodama1, Masakazu Tanaka1, Kimiko Izumo1, Toshio Matsuzaki2, Eiji Matsuura3, Hiroshi Takashima3, Shuji Izumo1, Ryuji Kubota1 (1.Kagoshima University, Joint Research Center for Human Retrovirus Infection, Division of Neuroimmunology, Japan, 2.Medical Corporation Sanshukai, Ohkatsu Hospital, Department of Neurology, 3.Kagoshima University Graduate School of Medical and Dental Sciences, Department of Neurology and Geriatrics)
Session information
English Poster Session
[Pe-10] English Poster Session 10 Neuroimmunology 07
Wed. May 19, 2021 6:15 PM - 6:55 PM Room 15 (ICC Kyoto 1F New Hall)
○Toshiaki Hirai1, Yoshiyuki Kuroiwa1, Yasuhisa Baba1, Hidetoshi Tahara2 (1.Departments of Neurology and Stroke Center, Mizonokuchi Hospital, Teikyo University School of Medicine,, Japan, 2.Department of Cellular and Molecular Biology, Graduate School of Biomedical Sciences, Hiroshima University)
○Satoshi Nozuma1,3, Eiji Matsuura1, Toshio Matsuzaki2, Ryuji Kubota2, Steven Jacobson3, Hiroshi Takashima1 (1.Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Japan, 2.Division of Neuroimmunology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 3.Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorder and Stroke, National Institutes of Health)
○Toshihiko Maeda, Masatoshi Omoto (Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan)
○Keiko Maruyama Saladini (Novartis Pharma K.K. Global Drug Development, Japan)
○Jin Nakahara1, Takahiko Saida2, Denis V. Sazanov3, Takayoshi Kurosawa4, Isao Tsumiyama4, Roman Willi5, Martin Zalesak5, Ratnakar Pingili6, Dieter A. Häring5, Krishnan Ramanathan5, Jun-ichi Kira7 (1.Department of Neurology, Keio University School of Medicine, Japan, 2.Kansai Multiple Sclerosis Center and Kyoto Min-iren Central Hospital, 3.Siberian District Medical Centre of the Federal Medical and Biological Agency of Russia, 4.Novartis Pharma KK, 5.Novartis Pharma AG, 6.Novartis Pharmaceuticals Corporation, 7.Translational Neuroscience Center, Graduate School of Medicine, International University of Health and Welfare and Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital)
○Takuya Matsushita1, Eizo Tanaka1, Noriko Isobe1, Mitsuru Watanabe1, Shoko Fukumoto1, Fumie Hayashi1, Ken Yamamoto2, Ryo Yamasaki1, Jun-ichi Kira1,3,4 (1.Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Japan, 2.Department of Medical Chemistry, School of Medicine, Kurume University, 3.2Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, 4.Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare)
○Atsuko Katsumoto1, Youwei Lin1, Wakiro Sato2, Tomoko Okamoto1, Takashi Yamamura2, Yuji Takahashi1 (1.Department of Neurology, National Center Hospital of Neurology and Psychiatry, Japan, 2.Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry)
○Kengo Ueda (Neuroscience Medical Franchise Dept. Medical Division, Novartis Pharma K.K., Japan)